Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2022 08:30 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

- Interim Data Anticipated by End of 2022 - - Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - AUSTIN, Texas, April 11, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma,...
March 23, 2022 16:05 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in the Cantor Rare Disease Symposium

AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew,...
March 10, 2022 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials

AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results...
March 10, 2022 09:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
February 23, 2022 09:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022

AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
January 05, 2022 09:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
November 10, 2021 17:06 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
November 03, 2021 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates

Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sitesSix-month primary outcome data readout from OraGrowtH210 expected 2H 2023...
October 21, 2021 16:05 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
September 02, 2021 08:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in September Investor Conferences

AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...